跳到正文
Sara Coca Membribes· @scocmem · X·· 22 小时前评分70

#ONCOALERTAF

正文 · 原文

Clinical trials rarely capture the full complexity of the patients we see in our practice. Great insights from @MarioBalsaMD on some of the challenges we face when evidence is limited. @OncoAlert #ESMO26

71 浏览 · 3 赞 · 2 转发 · 1 回复

引用@
🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials: 🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3 Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3 Immunotherapy is never just about the tumor 👇 #ESMO26 #Melanoma @DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
在 X 查看被引用的帖子
帖内回复
  1. Mario Balsa@MarioBalsaMD

    @scocmem @OncoAlert Sara thank you so much!!! Coming from you this means a lot! And completely agree, real life is always more complex than the trial population. So lucky to share #OncoAlertAF together ❤️

来源:Sara Coca Membribes · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org